David Knaack
Geen lopende functies
Profiel
David Knaack worked as a Senior Director of Research & Development at Osteotech, Inc. and as a Vice President of Product Development at Orthocon, Inc. He holds a doctorate degree from Cornell University and an undergraduate degree from St. Lawrence University.
Eerdere bekende functies van David Knaack
| Bedrijven | Functie | Einde |
|---|---|---|
Osteotech, Inc.
 Osteotech, Inc. Medical SpecialtiesHealth Technology Osteotech, Inc. develops biologic products for orthopedic, spinal, trauma, neurosurgical, and maxillofacial surgeons for use in surgical procedures. It operates in five segments: demineralized bone matrix, hybrid/synthetic, traditional tissue, spinal allograft, and client services. The company processes, markets, and distributes Xenograft bone tissue products, which are used as bone graft substitutes. The company was founded in 1986 and is headquartered in Eatontown, NJ. | Hoofd Techniek/Wetenschap/O&O | - |
Orthocon, Inc.
 Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Corporate Officer/Principal | - |
Opleiding van David Knaack
| St. Lawrence University | Undergraduate Degree |
| Cornell University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Orthocon, Inc.
Orthocon, Inc. Medical SpecialtiesHealth Technology Orthocon, Inc. designs, develops, and markets medical implantable devices. It provides implantable products designed to stop bone bleeding. The company was founded in 2005 and is headquartered in Irvington, NY. | Health Technology |
Osteotech, Inc.
Osteotech, Inc. Medical SpecialtiesHealth Technology Osteotech, Inc. develops biologic products for orthopedic, spinal, trauma, neurosurgical, and maxillofacial surgeons for use in surgical procedures. It operates in five segments: demineralized bone matrix, hybrid/synthetic, traditional tissue, spinal allograft, and client services. The company processes, markets, and distributes Xenograft bone tissue products, which are used as bone graft substitutes. The company was founded in 1986 and is headquartered in Eatontown, NJ. | Health Technology |
